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Background: In the current study, we evaluated the incremental value of blue dye injection in sentinel
node mapping of early breast cancer patients. We specially considered the experience of the surgeons
and lymphoscintigraphy results in this regard.
Methods: 605 patients with early stage breast cancer were retrospectively evaluated in the study. Pa-
tients underwent sentinel node mapping using combined radiotracer and blue dye techniques. Lym-
phoscintiraphy was also performed for 590 patients. Blue dye, radioisotope, and overall success rates in
identifying the sentinel lymph node were evaluated in different patient groups. The beneﬁt of blue dye
and radioisotope in identifying the sentinel lymph nodes was also evaluated.
Results: Marginal beneﬁts of both blue dye and isotope for overall sentinel node detection as well as
pathologically involved sentinel nodes were statistically higher in inexperienced surgeons and in pa-
tients with sentinel node visualization failure. In the patients with sentinel node visualization on lym-
phoscintigraphy, 6 sentinel nodes were detected by blue dye only. All these six nodes were harvested by
inexperienced surgeons. On the other hand 8 sentinel nodes were detected by dye only in the patients
with sentinel node non-visualization. All these nodes were harvested by experienced surgeons.
Conclusions: The use of blue dye should be reserved for inexperienced surgeons during their learning
phase and for those patients in whom lymphoscintigraphy failed to show any uptake in the axilla.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Sentinel node biopsy is the standard of care for axillary staging
in patients with early stage breast cancer. It avoids the morbidity
associated with axillary lymph node dissection in patients with
pathologically negative sentinel nodes [1,2].
Two commonly performed methods for sentinel node mapping
during surgery include use of the radiotracer alone or in combi-
nation with blue dye. Although each of these methods has been
used with acceptable results [3,4] several groups have recom-
mended that the combined approach can increase detection rate
and decrease false negative rate [5,6]. However the added value of
blue dyes over radiotracer alone technique is considered minimal
or “marginal” by few authors [7,8]. Although adverse reaction toþ98 5118933186.
minsadeghi1355@yahoo.com
ciates Ltd. Published by Elsevier Ltblue dyes are considerably less signiﬁcant than previously thought
[9,10] blue dye injection carries a risk of adverse reactions including
blue discoloration and tattooing of skin, and allergic reactions
[11,12].
In the current study, we evaluated the incremental value of blue
dye injection in sentinel node mapping of early breast cancer pa-
tients. We specially considered the experience of the surgeons and
lymphoscintigraphy results in this regard.2. Material and methods
605 patients (from March 2005 to March 2013) with early stage
breast cancer (diagnosed either by excisional biopsy or core needle
biopsy) were retrospectively evaluated. Patients underwent
sentinel node mapping using combined radiotracer and blue dye
techniques. Patients received intradermal injection of the 99mTc-
Antimony sulﬁde colloid (in 391 patients) or 99mTc-Phytate (in 214
patients) [13] (0.5 mCi for 1-day and 1 mCi for 2-day protocols).d. All rights reserved.
Table 1
Characteristics of the patients.
Number of patients 605
Age of the patients 47  18
Histology
Ductal 405
Lobular 185
Other 25
Type of biopsy
Core needle 482
Excisional 123
Tumor size 2.3  1.6
Patients with axillary involvement 119
Median number of harvested sentinel node in the patients (range) 1(1e4)
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1 min. Lymphoscintiraphy was also performed as described else-
where for 590 patients (using a dual head E.CAM Siemens or single
head SOPHA gamma camera) [14,15].
The sentinel nodes were harvested during surgery using a hand-
held gamma probe (RMD navigator or Europrobe) as well as blue
dye technique. For the blue dye technique, patients were injected
with Patent blue V (395 patients) or Methylene blue (210 patients)
after induction of anesthesia in a sub-dermal fashion. Harvested
sentinel nodes were sent to the pathologist for frozen section and/
or touch imprint cytology. Axillary lymph node dissection was
performed in patients with positive sentinel nodes.
Blue dye, radioisotope, and overall success rates in identifying the
sentinel lymph node were evaluated in different patient groups. The
beneﬁt of blue dye and radioisotope in identifying the sentinel lymph
nodes (overall as well as positive sentinel nodes) was also evaluated.
The study was approved by the local ethical committee of the
Mashhad University of Medical Sciences.
2.1. Statistical analysis
Continuous variables were expressed as mean  SD. Chi-square
test (or exact test) was used for comparison between groups. All
statistical analyses were performed by SPSS version 11.5 and p-
values less than 0.05 were considered statistically signiﬁcant.
3. Results
Table 1 shows the characteristics of included patients. Table 2
shows Dye, isotope, and overall success rates in identifying the
sentinel nodes. Overall detection rate was 86.4%, 91%, and 93.7% forTable 2
Dye, isotope, and overall success rates in identifying the sentinel nodes (the numbers ar
Dye success
N/total %
Experienced surgeons (n ¼ 545) MB 165/191 MB 89.1%
PB 320/354 PB 88.9%
Total 485/545 Total 89%
Inexperienced surgeons (n ¼ 60) MB 16/23 MB 64%
PB 22/37 PB 62.8%
Total 38/60 Total 63.3%
p-Value <0.0001
Sentinel node visualized on
lymphoscintigraphy
imaging (n ¼ 550)
MB 174/190 MB 92.5%
PB 334/360 PB 92.5%
Total 508/550 Total 92.4%
Sentinel node not visualized
on lymphoscintigraphy
imaging (n ¼ 40)
MB 5/14 MB 38.5%
PB 10/26 PB 37%
Total 15/40 Total 37.5%
p-Value <0.0001
MB: Methylene blue, PB: Patent blue V, P: 99mTc-phytate, AC: 99mTc-antimony sulﬁde coblue dye, radiotracer, and combinedmethod respectively. Detection
rates for methylene blue and patent blue V were 86.2%, and 86.6%
respectively (statistically non-signiﬁcant difference) and for 99mTc-
antimony sulﬁde colloid, and 99mTc-phytate were 91.3%, and 90.6%
respectively (statistically non-signiﬁcant difference). Detection rate
was statistically different between experienced and inexperienced
surgeons (experienced surgeons had passed the learning curve
period which encompassed axillary dissection in addition to
sentinel node biopsy in 30 patients). Experienced surgeons had
higher detection rate. Four experienced and three inexperienced
surgeons were involved in the study period. Detection rate was also
statistically higher in patients with visualized sentinel node on
lymphoscintigraphy images.
Table 3 shows the marginal beneﬁt of dye and isotope for
identifying sentinel nodes. Marginal beneﬁts of both blue dye and
isotope were statistically higher in inexperienced surgeons and in
patients with sentinel node visualization failure on lympho-
scintigraphy images. In the patients with sentinel node visualiza-
tion on lymphoscintigraphy, 6 sentinel nodes were detected by blue
dye only (1% of the harvested nodes). All these six nodes were
harvested by inexperienced surgeons. On the other hand 8 sentinel
nodes (16.3% of the harvested nodes) were detected by dye only in
the patients with sentinel node non-visualization. All these nodes
were harvested by experienced surgeons.
Marginal beneﬁts of blue dye and isotope were also statistically
higher for identifying involved sentinel nodes by inexperienced
surgeons and in patients with sentinel node visualization failure on
lymphoscintigraphy images (Table 4). In one patient with visual-
ized sentinel node on lymphoscintigraphy, the involved sentinel
node was identiﬁed by blue dye alone. This patient was also
operated on by an inexperienced surgeon.
Addition of blue dye, and radioisotope decreased the false
negative rate 4/114 (3.5%) and 7/114 (6.1%) respectively as shown in
Table 4.
4. Discussion
The rationale behind using two agents (radiotracer and blue
dye) for sentinel node mapping is to increase detection rate of
sentinel nodes and more importantly to decrease the false negative
rate of the procedure [5,16e19]. This approach is also valid for
sentinel node biopsy of other tumors besides breast cancer [20e
22]. Our study conﬁrmed this point as overall detection rate was
higher using the combined blue dye/radiotracer method. Blue dye
also contributed to detection of sentinel nodes which weree patients).
Isotope success Combined success
N/total % N/total %
P 179/185 P 93.7% e e
AC 333/360 AC 94%
Total 512/545 Total 94 519/545 95.2
P 15/25 P 65.2% e e
AC 24/35 AC 64.9%
Total 39/60 Total 65% 48/60 80%
<0.0001 <0.0001
P 184/188 P 96.8% e e
AC 348/362 AC 96.6%
Total 532/550 Total 96.7% 538/550 97.8%
P 5/13 P 35.7% e e
AC 8/27 AC 30.8%
Total 13/40 Total 32.5% 22/40 55%
<0.0001 <0.0001
lloid.
Table 3
Marginal beneﬁt of dye and isotope for identifying sentinel nodes (the numbers are
detected sentinel nodes).
Dye alone Isotope alone
N % N %
Experienced surgeons (n ¼ 580) 7 1.2 33 5.7
Inexperienced surgeons (n ¼ 70) 8 11.4 10 14
p-Value 0.00004 0.018
Sentinel node visualized on
lymphoscintigraphy imaging (n ¼ 583)
6 1 30 5.1
Sentinel node not visualized on
lymphoscintigraphy imaging (n ¼ 49)
8 16.3 10 20
p-Value <0.00001 <0.000001
Table 4
Marginal beneﬁt of dye and isotope for identifying involved sentinel nodes (the
numbers are involved sentinel nodes).
Number of involved
sentinel nodes
Dye alone Isotope alone
N % N %
Experienced surgeons 110 1 0.9 6 5.4
Inexperienced surgeons 14 3 21.4 1 7.1
p-Value 0.004 0.57
Sentinel node visualized on
lymphoscintigraphy imaging
107 1 0.9 5 4.6
Sentinel node not visualized on
lymphoscintigraphy imaging
14 3 21.4 1 7.1
p-Value 0.005 0.53
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false negative rate in 4 patients (Table 4).
Some groups have evaluated the sentinel node biopsy procedure
in breast cancer patients in order to identify sub-group of patients
who gain the most beneﬁt from addition of blue dye to the radio-
tracer technique [7,16,23,24].
Our results showed that addition of the blue dye to the radio-
tracer technique was much more beneﬁcial if the surgeon was
inexperienced (marginal beneﬁt of blue dye alone for detection rate:
11.4% vs. 1.2% and for detection of positive sentinel nodes: 21.4% vs.
0.9% for in-experienced and experienced surgeons respectively).We
considered passing a learning curve of 30 breast cancer patients
using sentinel node biopsy alongside axillary lymphnode dissection
as a criterionof surgeonexperience [25]. It has been shown that false
negative rate and detection failure of sentinel node mapping would
decrease after a learning phase of about 30e40 breast cancer pa-
tients [26,27]. Our result showed that using blue dye would not
contribute much to the sentinel node mapping in the hand of
experienced surgeons. Derossis et al. in a trend analysis also showed
the same ﬁnding [16]. They compared the marginal beneﬁt of blue
dye alone for overall detection rate as well as detection of positive
axillary sentinel nodes in the their ﬁrst 2000 breast cancer patients.
In their study marginal beneﬁt of blue dye alone for overall sentinel
node detection as well as detection of positive sentinel nodes
decreased steadily as the experience of the surgeons increased.
In another study by Teal et al. also demonstrated decreased
beneﬁt of blue dye as the experience of the surgeons grew. They
reported the results of combined blue dye/radiotracer sentinel
node mapping of 99 breast cancer patients and the added value of
blue dye over radioisotope alone (blue only sentinel nodes) was
only seen in their ﬁrst 57 patients [28]. Another study by Kang et al.,
on 3402 breast cancer patients showed that the surgeons are less
likely to use blue dye alongside radiotracer with increasing expe-
rience. In their study only 0.8% of patients with positive sentinel
nodes had blue only nodes [7].
In accordance to our ﬁnding, New Start program showed that
standard injection protocol (combined blue dye and radioisotope
technique) and multidisciplinary training can eliminate the
learning curve effect [29]. In our study, the inexperienced surgeons
didn’t have the multidisciplinary training as the New Start program
recommended and actually beneﬁted most from addition of blue
dye to the sentinel node mapping technique.
Another variable that we evaluated in our studywas the effect of
pre-surgical lymphoscintigraphy on the added value of blue dye
injection for sentinel node mapping. Overall detection rate was
considerably higher in patients with visualized sentinel node on
the lymphoscintigraphy images compared to those with non-
visualized sentinel node. This is in accordance to other studies
which demonstrated the strong predictive value of pre-operative
lymphoscintigraphy for sentinel node surgical detection success
[30,31]. The marginal beneﬁt of blue dye for detection of non-involved as well as pathologically involved sentinel nodes was
higher in patients with sentinel node non-visualization (16.3% vs.
1% and 21.4% vs. 0.9% respectively).
In a study by Goyal et al. 823 sentinel node procedures were
reported and blue only nodes were detected in 4% and 23% of pa-
tients with sentinel node visualization and non-visualization on
lymphoscintigraphy images respectively [30]. Their study supports
our results and they recommended adding blue dye injection to
sentinel node mapping in case of sentinel node non-visualization
on lymphoscintigraphy images.
Another study by Degnim et al. showed beneﬁt of blue dye
(blue/cold nodes) of 0.6% for sentinel node detection and 2.5% for
detection of pathologically involved sentinel nodes in patients with
sentinel node visualization on pre-surgical lymphoscinitgram [32].
Degnim et al. argued in their study that although the marginal
beneﬁt of blue dye injection in sentinel node mapping of breast
cancer is narrow, the beneﬁts outweigh the risks and they recom-
mended using blue dye even in case of sentinel node visualization
on lymphoscintigraphy.
In another study, Wu et al. reported their experience on 170
patients with visualized sentinel node on lymphoscintigraphy. In 6
patients, sentinel node could not be harvested during surgery. They
attributed these failures to “shine through effect”. More impor-
tantly, the harvesting failure of their group had a decreasing trend
(11.1%, 9.1%, and 1.4% for the ﬁrst, second, and third years, respec-
tively) [33]. Wu et al. results are in accordance to our ﬁndings and
show the importance of surgeon experience to ﬁnd visualized
sentinel nodes on lymphoscintigram during surgery.
In our opinion and based on the current evidence, decision to
use blue dye in addition to radiotracers in sentinel nodemapping of
breast cancer patients should be based on both surgeon experience
and ﬁndings on pre-operative lymphoscintigraphy images. In our
study, 8 sentinel nodes were only detected by blue dye alone in
patients whose sentinel node was visualized on lymphoscintig-
raphy and 2 of these nodes was pathologically involved. Interest-
ingly, all these 8 nodes were harvested by inexperienced surgeons.
This number was 6 nodes in case of sentinel node non-visualization
on pre-operative lymphoscintigraphy. Of these 6 nodes, 5 were
harvested by experienced surgeons. These results conﬁrm that in
the hands of competent and experienced surgeons, lympho-
scintigraphy can predict the success of sentinel node mapping us-
ing radiotracer alone and blue dye can be reserved for cases of
sentinel node non-visualization. On the other hand, inexperienced
surgeons would beneﬁt from addition of the blue dye during the
learning phase regardless of lymphoscintigraphy results.
In conclusion, addition of blue dye to radiotracer mapping can
increase the overall detection rate of sentinel nodes as well as
detection of pathologically involved nodes in breast cancer pa-
tients. However, the beneﬁt of blue dye use is limited in the hands
of experienced surgeons and in case of sentinel node visualization
on lymphoscintigram.Wewould therefore recommend that the use
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their learning phase and for those patients in whom lympho-
scintigraphy failed to show any uptake in the axilla.
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